83-5964-18　TNFSF13B, Belimumab Biosimilar 100ug　591700

特徴

• Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE).
• More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes.
• It is the first biological treatment approved for the indication of SLE.
• Concomitant use with live or inactivated vaccines must be avoided.
• Belimumab was FDA approved on March 9, 2011.
• Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass.
• Each heavy chain contains 452aa residues and each light chain contains 214aa residues.
• There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.
• Applications:Suitable for use in Functional Assays.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.